We are live on ! Find out more
BRA

Bender Robert & Associates Portfolio holdings

AUM $417M
1-Year Est. Return 25.02%
This Fund
S&P 500
This Quarter Est. Return
-22.5%
1 Year Est. Return
+25.02%
3 Year Est. Return
+98.12%
5 Year Est. Return
+139.29%
10 Year Est. Return
+812.75%
AUM
$262M
AUM Growth
-$89.5M
Cap. Flow
-$2.38M
Cap. Flow %
-0.91%
Top 10 Hldgs %
66.42%
Holding
56
New
11
Increased
4
Reduced
32
Closed
1

Top Buys

Rank Stock Value
1
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$708K
2
EOLS icon
Evolus
EOLS
+$296K
3
URGN icon
UroGen Pharma
URGN
+$282K
4
V icon
Visa
V
+$231K
5
AEP icon
American Electric Power
AEP
+$213K

Top Sells

Rank Stock Value
1
AAPL icon
Apple
AAPL
+$622K
2
AMZN icon
Amazon
AMZN
+$497K
3
MELI icon
Mercado Libre
MELI
+$333K
4
IDXX icon
Idexx Laboratories
IDXX
+$268K
5
GOOG icon
Alphabet (Google) Class C
GOOG
+$250K

Sector Composition

Rank Sector Weight
1 Technology 38.9%
2 Consumer Discretionary 25.33%
3 Healthcare 21.63%
4 Communication Services 11.08%
5 Utilities 1.34%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CLVS
51
DELISTED
Clovis Oncology, Inc.
CLVS
$90K 0.03%
+50,000
New +$73.8K
TOON icon
52
Kartoon Studios
TOON
$34.6M
$38K 0.01%
+5,000
New +$38.3K
JNCE
53
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$30K 0.01%
+10,000
New +$48.6K
CMRX
54
DELISTED
Chimerix, Inc.
CMRX
$22K 0.01%
+10,609
New +$34.1K
SMMT icon
55
Summit Therapeutics
SMMT
$10B
$14K 0.01%
+14,059
New +$19.7K
IDXX icon
56
Idexx Laboratories
IDXX
$44.9B
– –
-490
Closed -$268K
1 2
3

Similar funds

AWCI
Alpine Woods Capital Investors Purchase, New York $417M AUM 26.83% 1-Year Est. Return
ACM
Alight Capital Management New York $417M AUM 98.18% 1-Year Est. Return
PA
PSI Advisors Tampa, Florida $418M AUM 15.55% 1-Year Est. Return
CEI
Clark Estates Inc New York $416M AUM 6.04% 1-Year Est. Return
MCM
Millstreet Capital Management Boston, Massachusetts $418M AUM 80.77% 1-Year Est. Return
SSC
Spruce Street Capital New York $416M AUM
SCP
Stevens Capital Partners Omaha, Nebraska $416M AUM 18.93% 1-Year Est. Return
VM
Venator Management Pittsburgh, Pennsylvania $416M AUM 16.01% 1-Year Est. Return

Bender Robert & Associates's Q2 2022 Portfolio in Review

As of Q2 2022, Bender Robert & Associates held 56 positions worth $262M, down 26% from $351M the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Bender Robert & Associates's Q2 2022 filing shows 11 new, 4 increased, 32 reduced and 1 closed positions. Its largest new stake was BioCryst Pharmaceuticals: 68,600 shares worth $726K. The largest sale was Apple, an estimated $622K.

By sector, the portfolio is most concentrated in Technology at 39% of assets, up from 39% a quarter earlier, followed by Consumer Discretionary and Healthcare.

  • Bender Robert & Associates's largest Q2 2022 buy was BioCryst Pharmaceuticals: 68,600 shares worth $726K.
  • Bender Robert & Associates added most to Advanced Micro Devices in Q2 2022, an estimated $127K increase.
  • Bender Robert & Associates's biggest Q2 2022 reduction was Apple, cutting an estimated $622K.
  • Bender Robert & Associates fully exited Idexx Laboratories in Q2 2022, selling an estimated $268K.
  • Bender Robert & Associates's ten largest holdings make up 66% of its $262M portfolio in Q2 2022.
  • Bender Robert & Associates opened 11 new positions and closed 1 in Q2 2022.
  • Bender Robert & Associates's portfolio value fell 26% quarter-over-quarter to $262M.

Based on Bender Robert & Associates's 13F filing for Q2 2022, filed 19 Jul 2022.